Monday, Dec 22nd

Last update08:50:24 PM GMT






You are here: BioMedTech


$100m AstraZeneca blockbuster for Horizon

Dr Darrin M DisleyCambridge UK personalised medicines pioneer Horizon Discovery has landed a $100 million blockbuster deal with global pharma giant AstraZeneca.

Kymab clinches Novo Nordisk millions

Professor Allan Bradley, Emeritus Director of the Wellcome Trust Sanger InstituteCambridge-based BiomedTech business Kymab has gained further commercial traction after selling its mouse-based antibody technology to global pharma company Novo Nordisk.

US boost for cannabis-based cancer spray

Cannabis-based spray gaining traction for GWA cancer spray delivering a cannabis-based medicine – developed by a Cambridge UK medical technology business – has won a key patent approval in the US.

Cambridge Cognition raises £6.4m in AIM IPO

Management team at Cambridge CognitionHealthcare technology specialist Cambridge Cognition Holdings raised £6.4 million on its AIM IPO as the shares made their UK bow today at a placing price of 70p.

Entrepreneurs tackle digital healthcare

Dr Claire NovorolThe Centre for Entrepreneurial Learning (CfEL) at Cambridge Judge Business School has teamed up with, as well as a host of industry leaders and design experts, to create a fantastic opportunity to explore and develop digital health technology.

New Cambridge hub for cancer tech powerhouse

The new Jonas Webb Building on the Babraham Research CampusCancer Research Technology Limited – the technology development and commercialisation arm of Cancer Research UK – has moved its Cambridge drug discovery activity into a new chemistry-focused building on the Babraham Research Campus.

Personalised medicines gospel reaches Vatican

Photograph by DAVID ILIFF. License: CC-BY-SA 3.0Personalised medicines technology from Horizon Discovery division Horizon Diagnostics (HDx) in Cambridge UK can now be distributed in Vatican City as part of a new deal with an Italian partner.

Law change boost for cannabis medicine

GW chairman, Geoffrey GuyCambridge medical technology company GW Pharmaceuticals can now sell its cannabinoid-based products with less restriction in the UK thanks to a significant tweak in the law.

Page 52 of 134